Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Agios is implementing good security practices.
Read more about the latest issues in cybersecurity
Personally identifiable information (PII) is data that could identify a specific individual. ...
A man-in-the-middle attack (MITM attack) is a cyber attack where an attacker relays and possibly ...
Compare Agios's security performance with other companies